Essent Biologics, a leading supplier of adult human-derived cell and scaffold materials announced it has launched a new line of primary cells: Wharton's jelly-derived Mesenchymal Stromal Cells (hWJMSC), to its growing product portfolio.

Isolated from human umbilical cord tissue, Essent's hWJMSCs originate from a single donor and are proven to differentiate in vitro toward chondrogenic, osteogenic and adipogenic lineages. In addition, these cells have a unique secretory profile with anti-inflammatory properties–making them extremely attractive for both research and therapeutics within the regenerative medicine and tissue engineering fields.

"Our strong partnership with AlloSource allows us access to donated placentas from their Placenta Donation Program, sourcing from women 30 years and younger," said Courtney Jurbala, Vice President of Business Operations. "We collect the cells from the research-consented donated placenta, after a new life has been born and the mother goes home with her baby. The miracle of life continues to advance the field of regenerative medicine with a simple donation."

Rigorously characterized to ISCT guidelines, Essent's hWJMSCs are validated to guarantee at least one million cells per vial post thaw at low passage. In addition, Essent offers flash-frozen origin tissue as a companion product for each lot of cells, the Essent Origin Sample™, so that researchers always know their source.

Essent's non-GMP hWJMSC are available immediately for purchase, with GMP available June 2022.